Lithium Toxicity and Side Effects: GPAT Pharmacology Guide

Introduction to Lithium Carbonate

Lithium is the lightest alkali metal and a gold standard mood stabilizer in psychiatry. It is primarily prescribed for the treatment of acute mania and the long-term prophylaxis of bipolar affective disorder (BPAD).

For pharmacy and medical exams like GPAT and NIPER, lithium is one of the most frequently tested topics. This is due to its narrow therapeutic index, extensive side-effect profile, and life-threatening toxicity risks. Understanding its pharmacokinetics, monitoring parameters, and clinical side effects is essential for scoring high in psychiatric pharmacology.

---

Mechanism of Action of Lithium

Unlike traditional neurotransmitter receptor blockers, lithium works inside the cell. It affects secondary messenger signaling cascades in the brain.

1. Inositol Depletion Hypothesis

• Lithium inhibits the enzyme Inositol Monophosphatase (IMPase).
• It also blocks Inositol Polyphosphate 1-phosphatase.
• This prevents the recycling of inositol and depletes free intracellular inositol.
• Consequently, it decreases the synthesis of Phosphatidylinositol 4,5-bisphosphate ($PIP_2$).
• This reduces the generation of two vital second messengers: Inositol trisphosphate ($IP_3$) and Diacylglycerol (DAG).
• Hyperactive neuronal signaling pathways in mania are effectively quieted.

2. Inhibition of Glycogen Synthase Kinase-3 (GSK-3)

• Lithium directly inhibits the enzyme GSK-3$\beta$.
• Inhibition of GSK-3$\beta$ promotes neuroprotection and neuroplasticity.
• It upregulates brain-derived neurotrophic factor (BDNF) and exerts anti-apoptotic effects.

---

Pharmacokinetics and Therapeutic Drug Monitoring (TDM)

Lithium handling in the human body mirrors that of sodium ions ($Na^+$).

• Absorption: Completely and rapidly absorbed from the gastrointestinal tract.
• Distribution: Distributes uniformly in total body water without binding to plasma proteins.
• Metabolism: Lithium undergoes zero hepatic metabolism.
• Excretion: Excreted almost entirely (95%) unchanged via the kidneys.
• Renal Reabsorption: Approximately 80% of filtered lithium is reabsorbed in the proximal convoluted tubule (PCT). It competes directly with sodium for reabsorption.

Therapeutic Serum Concentration Window

Because lithium has a very low therapeutic ratio, Therapeutic Drug Monitoring (TDM) is mandatory.

Clinical State	Target Serum Lithium Level
Acute Mania (Treatment)	0.8 to 1.2 mEq/L
Bipolar Maintenance (Prophylaxis)	0.6 to 0.8 mEq/L
Early Toxicity Signs	> 1.5 mEq/L
Severe / Fatal Toxicity	> 2.0 to 2.5 mEq/L

Blood samples for lithium monitoring are drawn 12 hours after the previous evening dose (trough level).

---

Important Side Effects of Lithium

Side effects occur commonly even within therapeutic ranges. GPAT questions frequently test these organ-specific adverse reactions:

1. Neurological Side Effects

• Fine Tremors: A classic early sign. Usually involves fingers and hands. Controlled by adding a non-selective beta blocker like Propranolol.
• Muscle Weakness: Transient fatigue and lethargy.
• Motor Incoordination: Worsening hand ataxia suggests impending toxicity.

2. Renal Side Effects

• Nephrogenic Diabetes Insipidus (NDI): Lithium accumulates in renal collecting duct principal cells via epithelial sodium channels (ENaC). It blocks vasopressin (ADH)-dependent cyclic AMP formation and impairs Aquaporin-2 water channels.
• Clinical signs include marked polyuria (excess urine) and polydipsia (excess thirst).
• Drug of Choice for Lithium-Induced NDI: Amiloride. Amiloride blocks ENaC channels, preventing lithium from entering renal cells.

3. Endocrine Side Effects

• Hypothyroidism and Goitre: Lithium blocks thyroid iodine uptake, iodotyrosine coupling, and thyroid hormone release ($T_3$ and $T_4$). Patients develop elevated Thyroid-Stimulating Hormone (TSH). Treat with daily Levothyroxine; lithium discontinuation is rarely required.
• Weight Gain: Common in chronic treatment.

4. Teratogenic Effects (Pregnancy Warning)

• Lithium crosses the placenta freely.
• Taken in the first trimester, it causes Ebstein's Anomaly.
• This is a congenital heart defect marked by downward displacement of the tricuspid valve into the right ventricle, causing severe tricuspid regurgitation and "atrialization" of the right ventricle.

5. Hematological Side Effects

• Benign Leukocytosis: Lithium stimulates granulocyte colony-stimulating factors, producing an elevated neutrophil count.

---

Lithium Toxicity: Symptoms and Treatment

Lithium toxicity develops rapidly when renal clearance decreases or dosing exceeds safety limits.

Signs of Mild-to-Moderate Toxicity (1.5 – 2.0 mEq/L)

• Persistent coarse tremors
• Nausea, persistent vomiting, and severe diarrhea
• Slurred speech, drowsiness, and muscle twitching

Signs of Severe Toxicity (> 2.0 mEq/L)

• Hyperreflexia and gross ataxia
• Generalized convulsions and seizures
• Oliguria, circulatory collapse, coma, and death

Management of Lithium Poisoning

1. Stop Lithium Immediately: Discontinue all doses.
2. Hydration: Infuse normal saline (0.9% NaCl) intravenously to replenish sodium and volume, promoting lithium excretion.
3. Avoid Diuretics: Never give loop or thiazide diuretics.
4. Hemodialysis: The definitive treatment of choice for severe lithium poisoning (levels > 2.5–4.0 mEq/L or in patients with acute renal failure).

---

High-Yield Drug Interactions for GPAT

Any factor or drug that lowers renal sodium reabsorption or volume triggers proximal tubular lithium reabsorption, precipitating toxicity.

• Thiazide Diuretics: Inhibit sodium reabsorption in the distal tubule. The PCT compensates by reabsorbing more sodium and lithium, leading to acute lithium toxicity.
• NSAIDs (e.g., Indomethacin, Ibuprofen): Inhibit renal prostaglandins, reduce renal blood flow and GFR, and decrease lithium clearance.
• ACE Inhibitors and ARBs: Reduce aldosterone and renal perfusion, elevating serum lithium.
• Safe Analgesic Alternative: Paracetamol does not alter lithium clearance and is the painkiller of choice.
• Osmotic Diuretics (Mannitol) & Carbonic Anhydrase Inhibitors (Acetazolamide): Increase renal lithium excretion, lowering lithium blood levels.